Full Text View
Tabular View
Study Results
Related Studies
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia
This study has been completed.
Study NCT00970632   Information provided by Eli Lilly and Company

First Received on September 1, 2009.   Last Updated on March 8, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Benign Prostatic Hyperplasia (BPH)
Additional conditions recognized in this trial
Hyperplasia
Prostatic Hyperplasia
More general conditions related to this trial
Genital Diseases, Male
Pathologic Processes
Prostatic Diseases
Interventions listed in this trial
Tadalafil 5 mg
Placebo tablet
Tamsulosin
Placebo capsule
Additional drug interventions recognized in this trial
Tadalafil
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Cardiovascular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Physiological Effects of Drugs
Therapeutic Uses
Vasodilator Agents
Sponsors listed in this trial
Eli Lilly and Company


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services